StockNews.com Begins Coverage on DURECT (NASDAQ:DRRX)

Stock analysts at StockNews.com assumed coverage on shares of DURECT (NASDAQ:DRRXGet Free Report) in a research report issued to clients and investors on Saturday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright reissued a “neutral” rating on shares of DURECT in a research report on Thursday, November 14th.

Check Out Our Latest Stock Analysis on DURECT

DURECT Stock Performance

DURECT stock opened at $0.95 on Friday. The firm’s 50 day moving average price is $1.11 and its two-hundred day moving average price is $1.32. The firm has a market cap of $29.49 million, a PE ratio of -1.56 and a beta of 1.01. DURECT has a twelve month low of $0.49 and a twelve month high of $1.88.

Institutional Trading of DURECT

Several large investors have recently added to or reduced their stakes in DRRX. International Assets Investment Management LLC lifted its stake in shares of DURECT by 41.3% in the 2nd quarter. International Assets Investment Management LLC now owns 21,550 shares of the specialty pharmaceutical company’s stock valued at $28,000 after purchasing an additional 6,300 shares during the last quarter. Geode Capital Management LLC raised its holdings in DURECT by 4.8% during the third quarter. Geode Capital Management LLC now owns 319,905 shares of the specialty pharmaceutical company’s stock valued at $429,000 after buying an additional 14,658 shares in the last quarter. Finally, Richmond Brothers Inc. boosted its stake in shares of DURECT by 39.5% during the 2nd quarter. Richmond Brothers Inc. now owns 1,072,014 shares of the specialty pharmaceutical company’s stock worth $1,383,000 after acquiring an additional 303,670 shares in the last quarter. 28.03% of the stock is owned by institutional investors.

About DURECT

(Get Free Report)

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.

Further Reading

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.